​

Eterna Therapeutics Stock (NASDAQ:ERNA)

RevenueOwnershipFinancialsChart
Eterna Therapeutics by TradingView

Previous Close

$2.37

52W Range

$2.08 - $39.45

50D Avg

$3.02

200D Avg

$8.38

Market Cap

$9.52M

Avg Vol (3M)

$28.67K

Beta

7.12

Div Yield

-

ERNA Company Profile

Brooklyn ImmunoTherapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing therapies to treat patients with cancer. Its advanced program is IRX-2 that is in a Phase 2b clinical trial in patients with squamous cell cancer of the head and neck. The company also develops therapies using gene-editing and cell therapy technology for the treatment of oncology, blood disorder, and monogenic disease. Brooklyn ImmunoTherapeutics, Inc. is based in Brooklyn, New York.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

6

IPO Date

Aug 29, 1991

Website

ERNA Performance

ERNA Financial Summary

Dec 24Dec 23Dec 22
Revenue$582.00K$68.00K-
Operating Income$-15.67M$-21.14M$-33.22M
Net Income$-44.55M$-21.67M$-24.58M
EBITDA$-15.67M$-19.93M$-33.22M
Basic EPS$-3.26$-4.08$-8.06
Diluted EPS$-3.26$-4.08$-8.06

Fiscal year ends in Dec 24 | Currency in USD

Peer Comparison

TickerCompany
TCRXTScan Therapeutics, Inc.
RNAZTransCode Therapeutics, Inc.
RCUSArcus Biosciences, Inc.
APLSApellis Pharmaceuticals, Inc.
RLAYRelay Therapeutics, Inc.
ZVSAZyVersa Therapeutics, Inc.
DAWNDay One Biopharmaceuticals, Inc.
ANNXAnnexon, Inc.
PHIOPhio Pharmaceuticals Corp.
IMMXImmix Biopharma, Inc.
GPCRStructure Therapeutics Inc.
XFORX4 Pharmaceuticals, Inc.
ITOSiTeos Therapeutics, Inc.
REVBRevelation Biosciences, Inc.
CGEMCullinan Oncology, Inc.
INZYInozyme Pharma, Inc.
ABOSAcumen Pharmaceuticals, Inc.
UNCYUnicycive Therapeutics, Inc.
ZURAZura Bio Limited
PALIPalisade Bio, Inc.